Literature DB >> 22124288

Ketamine-induced biliary dilatation: from Hong Kong to New York.

Ellen Gutkin1, Syed A Hussain, Sang H Kim.   

Abstract

Ketamine is a popular drug of abuse in China, especially for young adults between the 18 and 30 years. It produces desirable short-term sensations of excitement, dream-like states, hallucinations, and vivid imagery, but is also responsible for untoward effects of the gastrointestinal and urinary tracts. Abusers often present with severe abdominal pain and dysuria. In addition to its excretion in urine, ketamine is also excreted in bile and can lead to biliary dilatation. Sixteen reports of this phenomenon have been described in the literature, mostly in China. To date, this phenomenon has not been described in the United States. We present 2 cases of ketamine-induced biliary dilatation in young adult Asian patients. It is a new entity in the United States but should be recognized early, as it may prevent unnecessary investigation with blood work, imaging, therapeutic endoscopy, or even surgery.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22124288     DOI: 10.1097/ADM.0b013e3182399216

Source DB:  PubMed          Journal:  J Addict Med        ISSN: 1932-0620            Impact factor:   3.702


  3 in total

1.  Ketamine as a possible cause of cirrhosis in a patient with chronic pain.

Authors:  Roisin Bevan; Denis Burke
Journal:  Frontline Gastroenterol       Date:  2013-12-10

Review 2.  Intravenous hypnotic regimens in patients with liver disease; a review article.

Authors:  Hassan Soleimanpour; Saeid Safari; Farzad Rahmani; Asghar Jafari Rouhi; Seyed Moayed Alavian
Journal:  Anesth Pain Med       Date:  2015-02-24

3.  Repeated or Continuous Medically Supervised Ketamine Administration Associated with Hepatobiliary Adverse Events: A Retrospective Case Series.

Authors:  Samantha Cotter; Jennie Wong; Neha Gada; Rajdeep Gill; S Christopher Jones; Grace Chai; Daniel Foster; Mark Avigan; Mallika Mundkur
Journal:  Drug Saf       Date:  2021-10-26       Impact factor: 5.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.